title: Quantitative determination of telomerase activity in breast cancer and benign breast diseases.
abstract: Telomerase plays an important role in maintaining the stability of chromosomes. This ribonucleoprotein prevents chromosome ends (telomeres) from gradual loss with each cell division. It enables tumor cells to maintain telomere length, allowing indefinite replicative capacity. Telomerase activity has been detected in the majority of tumor and germ cells and in immortalized cell lines. Quantitative telomerase PCR-ELISA (TeloTAGGG Telomerase PCR ELISA(PLUS)) was evaluated for distinguishing benign and malignant breast tissue. Activity of telomerase was determined in 27 samples of fibrocystic and dysplastic tissues, 28 fibroadenomas and phylloid tumors, and 154 breast cancer tissues; 59 specimens were analyzed retrospectively. Analytical precision and linearity of the assay was tested using breast carcinoma cell line ZR-75-1 and breast tumor tissue extracts. About 4% of tumor samples were excluded from analysis due to interferences in the PCR reaction. Relative telomerase activity differed significantly in the groups of dysplastic tissues, fibroadenomas and carcinomas. The highest activity was found in breast cancer tissue. This method can identify breast cancer tissue with 73% clinical sensitivity and 93% specificity as compared to benign breast tumors. We did not find a correlation between telomerase activity and the tissue levels of estrogen and progesterone receptors, HER-2/neu oncoprotein concentration, tumor size, and lymph node positivity. Probability of disease-free survival was significantly lower for patients with telomerase activity higher than median value. As the assay for telomerase activity has very high analytical sensitivity and high specificity for cancer cells, this routinely used method may prove useful for distinguishing malignant phenotype of breast tissues.
authors.affiliation: Masaryk Memorial Cancer Institute, Brno, Czech Republic. simickom@mou.cz
authors.forename: M
authors.initials: M
authors.lastname: Simícková
authors.forename: M
authors.initials: M
authors.lastname: Nekulová
authors.forename: L
authors.initials: L
authors.lastname: Pecen
authors.forename: M
authors.initials: M
authors.lastname: Cernoch
authors.forename: M
authors.initials: M
authors.lastname: Vagundová
authors.forename: Z
authors.initials: Z
authors.lastname: Pacovský
mesh_terms: D001941:Breast Diseases / Q000175:diagnosis / Q000201:enzymology / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D002277:Carcinoma / Q000175:diagnosis / Q000201:enzymology / Q000473:pathology; D004796:Clinical Enzyme Tests / Q000379:methods*; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D018226:Fibroadenoma / Q000175:diagnosis / Q000201:enzymology / Q000473:pathology; D006801:Humans; D016133:Polymerase Chain Reaction / Q000379:methods; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000032:analysis*; D014407:Tumor Cells, Cultured
chemical_list: D019098:Telomerase